Aquivia Health Review

Aquivia Health: a compounded GLP-1 platform that also stocks the brand-name pens

Most telehealth platforms pick a lane: they either sell low-cost compounded semaglutide and tirzepatide, or they help you get the brand-name pens. Aquivia Health is unusual because it carries both side by side. You can start on compounded therapy at $149 a month and, if you'd rather have FDA-approved Ozempic or Zepbound, you can step up to those through the same account. That flexibility is the single most interesting thing about this provider, and it's the reason it's worth a look — but it launched in April 2026, so you're an early customer, and there are some real gaps in what the company discloses publicly.

How the pricing actually works

Aquivia uses a flat per-drug model, which is refreshingly simple. Compounded semaglutide is $149 a month no matter what dose you're on, and compounded tirzepatide runs a bit higher at a low-three-figure monthly rate — also flat across every dose. That matters because a lot of competitors quietly raise your price as you titrate up to a higher dose. Here, the number you start with is the number you keep. The monthly price includes the medication, the clinician consult, and free shipping, so there's no separate consultation fee bolted on and no insurance to deal with — it's a straight self-pay arrangement.

For context, the category median for a provider like this sits around $169 a month, so Aquivia's compounded semaglutide comes in under the typical price. If you're confident you'll stay on treatment, the company also publishes a 52-week prepay option: you pay one lump sum up front for thirteen shipments, which lowers the effective per-shipment cost versus paying every four weeks. It's a real saving, but only commit to it once you know the medication agrees with you — prepaying a year of GLP-1 before you've felt how your body reacts is a gamble.

Compounded versus brand — and why that choice is here at all

The two compounded options are the everyday-affordable path. The brand-name path is dramatically more expensive: Ozempic and Zepbound through Aquivia each carry a high-four-figure monthly price, which is roughly in line with paying cash retail anywhere. That's not a knock on Aquivia — branded GLP-1s are simply costly without insurance — but be clear-eyed that the brand option here is a convenience, not a discount. The genuine value is having one provider where you can begin on compounded therapy and switch to the FDA-approved pen later without starting a whole new intake somewhere else.

• Compounded semaglutide — $149/mo, flat across all doses, the cheapest way in.
• Compounded tirzepatide — low-three-figure monthly, billed as the most popular choice among members.
• Branded Ozempic / Zepbound — high-four-figure monthly, FDA-approved, essentially cash-retail pricing.

Who's actually behind it

Aquivia scores points for not hiding its team. Clinical care runs through Open Loop Healthcare Partners, PC — an established managed-services clinician network that also powers several other telehealth brands, so the doctors writing prescriptions aren't an anonymous gig pool. The founding trio is named publicly: Steven Bishop, MD as Chief Medical Officer (internal medicine, metabolic and longevity focus), Phillip Gray, PharmD as Chief Pharmacist (a compounding and USP-compliance background), and Tom Foster as President on the operations side. Naming a pharmacist co-founder with 503A experience is a stronger trust signal than most compounded startups bother to offer.

The disclosure gaps you should weigh

Here's where honesty is owed. Aquivia does not publicly name the specific 503A compounding pharmacy that fills your prescription — the marketing talks about a '503A standard' and 'licensed compounding pharmacies' in the abstract, but there's no named partner you can look up against a state board. There are also no LegitScript, PCAB, or BBB badges visible on the site, which is a notable omission for a self-pay compounded-GLP-1 platform. And there's a branding wrinkle: the site's underlying Schema.org markup names a parent called 'CatalystMD' even though everything customer-facing says Aquivia Health, and the company doesn't explain that relationship anywhere public. None of these are red flags of wrongdoing, but together they're why our verification confidence on this provider is low rather than high.

The FDA reality on the compounded options

Be clear about what compounded means. Compounded semaglutide and tirzepatide are not FDA-approved and have not been reviewed by the FDA for safety or efficacy. The FDA has specifically warned that compounded GLP-1s prepared outside proper 503A/503B frameworks have been linked to dosing errors and adverse events — and because Aquivia doesn't name its pharmacy, you can't independently confirm that pharmacy's licensure before you enroll. The branded Ozempic and Zepbound routes don't carry that uncertainty: Zepbound is FDA-approved for chronic weight management, and Ozempic is FDA-approved for type 2 diabetes (its weight-loss use is off-label, at the clinician's discretion).

State availability is a question mark until you sign up

Aquivia says it operates nationwide 'where allowed by state law,' but it publishes no list of which states actually qualify. You only find out whether your state is eligible by completing the intake. To the company's credit, it states plainly that finishing the health check does not guarantee a prescription — that's the kind of caveat you want a responsible telehealth provider to make. But practically, it means you can't confirm you're even serviceable before handing over your information. Note too that only the weight-loss program is live today; the advertised longevity and dysautonomia/POTS pathways are waitlist-only.

Who should choose Aquivia — and who should skip it

Consider Aquivia if you want low flat-rate compounded GLP-1 pricing with a named clinical team, and you specifically value being able to move to brand-name pens down the road without switching providers. The under-median monthly cost and the no-extra-consult-fee structure make it a reasonable everyday option for self-pay patients.

Skip it, or at least wait, if you need to confirm your state is covered before sharing personal details, if you want a named, verifiable compounding pharmacy, or if third-party trust badges and an established review history are non-negotiable for you. A five-week-old platform with no Trustpilot or BBB profile yet is, by definition, unproven — early adopters get the price, but they also absorb the uncertainty.

Bottom line

Aquivia Health is a promising, fairly priced newcomer with a genuinely useful compounded-or-brand structure and unusually transparent leadership. What holds it back is disclosure: no named pharmacy, no public state list, no trust badges, and a parent-brand mismatch the company hasn't explained. If those don't bother you and your state turns out to be eligible, the flat $149-a-month compounded pricing is a fair deal. If you want maximum verifiability, give it a few months to publish the missing details — and read our scoring methodology to see exactly how we weigh these gaps.

For a side-by-side, Yucca Health ($146/month) and Found ($149/month) are the most comparable options to weigh against Aquivia Health.